Kathy’s Latest Speaking Engagements, Writing, and Upcoming Events
Recent Publications and Articles
Kathy Giusti founded the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC) after she was diagnosed with multiple myeloma, a form of blood cancer, in 1998. Twenty years later, Kathy is in complete remission.
Read More
Oct. 4 2018 | STAT Precision medicine, also known as personalized medicine, has the potential to transform how we treat — or even cure — cancer and a host of other diseases such as cystic fibrosis, Parkinson’s, and Alzheimer’s.
Read More
Kathy Giusti joins deep dive discussion on the advancement of Precision Medicine with other visionaries in the field. The panel was moderated by Dr. David B. Agus, University of Southern California and NBC News correspondent.
Read More
When Kathy Giusti was diagnosed with multiple myeloma, a type of blood cancer, at age 37, doctors told her she probably had three years to live. Now, more than 20 years later, with her disease in remission, she spends her days working to raise funds and improve research and treatments for cancer. In her down […]
Read More
In 1996, Kathy Giusti, then a 37-year-old pharmaceutical sales exec with a new baby, was told she had a blood cancer called multiple myeloma and three years to live. She refused to act like her life was over. “I decided I was going to live like I was going to live, not like I was […]
Read More
Currently, executive women hold only about 4.6% of CEO positions in S&P 500 companies. Research from McKinsey & Company reports that at the first critical step up to manager, women are 18% less likely to be promoted than their male peers. This gender disparity has a dramatic effect on the representation of women: if entry-level […]
Read More
The innovative form of trial design known as a master protocol is gaining attention, particularly in oncology. “The widespread availability of next-generation genomic sequencing has opened the door to the development of precision oncology,” as experts have noted.
Read More
The Kraft Precision Medicine Accelerator aims to speed up the development and delivery of cancer therapies by improving the business processes that surround them. With billions of dollars spent on the development of precision medicine and related cancer research over the last decade, a recent partnership seeks a new way to bring these treatments to […]
Read More
The Harvard Business School’s Kraft Precision Medicine Accelerator is tackling a series of initiatives that will position patients to help drive improvements in both clinical care and clinical research.
Read More
The best consumer brands help savvy shoppers find exactly what we need, exactly when we want it. If we buy a dress, for example, from our favorite online retailer, we’re likely prompted to purchase other items we had never thought of—a matching pair of shoes, the perfect statement necklace—that brings it all together. It may […]
Read More
“It is well understood that achieving the full potential of precision medicine for all cancer patients depends on the sharing of patients’ genomic and molecular data and clinical information. To this end, several efforts — including the Genomic Data Commons, ORIEN, and CancerLinQ — have been established to facilitate data sharing among clinicians and researchers […]
Read More
Why do some patients succumb to their cancer in a matter of months, while others with the same disease live for years or even decades? These disparities, we now know, can be explained by the mutated genes and other abnormalities that drive a cancer’s growth and fuel its spread. Patients can increasingly be matched to […]
Read More
From bold investors to company builders, from research scientists to patient advocates, Kathy is recognized with nearly three dozen women and men who are driving progress in medicine.
Read More
The world of cancer care is not moving nearly as fast as it could. Right now, in order to make new therapies,scientists need as much data as possible to identify patterns and targets, but the clinical and genetic information of cancer patients is siloed, with the vast majority of pharmaceutical companies, academic medical centers, hospitals, […]
Read More
Kathy lays out how innovative models are overcoming challenges of data sharing in an interview with Precision Medicine World Conference April 2017
Read More
When it comes to cancer, all knowledge is power — even when that knowledge is scary. Knowing as much as you can about cancer lets you and your health care team act decisively in devising your treatment strategy. Even more important, it lets you act specifically in selecting treatments or clinical trials that might be […]
Read More
Lifestyles Magazine features Kathy in “Patient Power,” highlighting the data-driven model of the MMRF, and Kathy’s efforts to extend this model across all cancers.
Read More
Kathy discusses how direct-to-consumer best practices can help cancer organizations connect directly with patients to fuel research progress.
Read More
Organizations striving to find new ways to attack cancer have much to learn from direct-to-consumer (DTC) companies. Specifically, they can profit from DTC firms’ expertise in persuading their customers to provide and share their data. This is something many cancer patients don’t do because they are unaware of the data’s importance or their power to […]
Read More
Location, location, location. It’s the number one rule in real estate and a common refrain sung by agents and choosy homebuyers alike. But it should also be the mantra for people with cancer
Read More
Scientific efforts to find cures for cancer will be severely hampered if the scientific community does not change the ways in which patient data is collected, shared, and analyzed.
Read More
Finding the perfect black dress is no small feat, but it’s gotten a whole lot easier. Instead of spending a good chunk of my Saturday morning at the mall, I can browse online or tap an app and be presented with the right dress for the right occasion..
Read More
HBS names Kathy the first Henry and Allison McCance Family Senior Fellow of Business Administration.
Read More
Business Insider discusses Kathy’s urgency to drive progress for Patients. A Woman who was given 3 years to live in 1996 explains how her ‘death sentence’ made her one of the world’s best leaders.
Read More
Kathy is profiled by Adam Bryant in the New York Times: Kathy Giusti: Sharing Life Lessons from a Death Sentence
Read More
Kathy and former Time Warner CEO, Dick Parsons, highlight the important of sharing data and how the MMRF precision medicine model is a leading model for all cancers.
Read More
Kathy Giusti name 1 of 3 Top Disruptors in Medicine by Fortune magazine.
Read More
Kathy Giusti: The Cancer Patient Who Became an Advocate for Precision Medicine
Read More
On Thursday, President Obama hosted a summit at the White House on his Precision Medicine Initiative (PMI), the year-old effort to treat and prevent disease based on individual differences in genetics, environment and lifestyle.
Read More
In an interview with STAT, Kathy explains why applying a business approach to cancer research is critical.
Read More
Precision Medicine World Conference International interviews Kathy Giusti for LinkedIn on how innovative models bring precision medicine to all patients.
Read More
It’s a different world than when I was diagnosed in 1996 with the incurable cancer multiple myeloma. Today, thanks to advances in sequencing technologies, we have gained unprecedented insights into the genetic drivers of cancer
Read More
In an increasingly digital age, immediacy has become the name of the game. A simple Google search gives us answers instantaneously and the cloud allows us to store and recover information at the drop of a hat. We take these for granted, but scientists and medical professionals do not have these luxuries when they are […]
Read More
Featured in the Wall Street Journal, MMRF Co-Founders, Kathy Giusti and Karen Andrews discuss the importance of becoming active participants in the research process.
Read More
We’ve seen how dramatically patients’ lives can change when they are matched with the right treatment at the right time in their disease course. Although this is still an exception and not the rule, we believe collaborative research approaches will make this kind of precision medicine a reality for all patients with cancers.
Read More
Many of you have heard about Tom Brokaw’s new book A Lucky Life Interrupted. In it he writes with gratitude about his cancer journey, from the shocking moment of his devastating diagnosis to the triumph of learning his disease was in remission.
Read More
Despite the fact that one in every two men and one in every three women will be diagnosed with cancer in their lifetime, no one ever expects it to happen to them. I surely didn’t. I was an otherwise healthy 37-year-old when I was diagnosed in 1996 with multiple myeloma, the same rare cancer Tom […]
Read More
Every day, more and more of the nearly 15 million men, women and children who are diagnosed with cancer are taking important steps to bank their tissue, and to sequence their cancer genome as part of their cancer cure. These data are being used to match some patients to the most effective treatment possible allowing […]
Read More
Critics may call this “needle in a haystack” discovery work much too speculative, but developing a 1 million-plus patient repository of genetic information could help researchers develop drugs and treatments for cancer and other diseases tailored to individual patients.
Read More
Kathy Giusti #19 on List of “The World’s 50 Greatest Leaders” Fortune, March 2014
Read More
Kathy Giusti Named to the 2011 TIME 100 TIME Magazine
Read More
